Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
64
Frequently Asked Questions
What is Market Cap of Aclaris Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Aclaris Therapeutics Inc market cap is $227.5M.
What is the 52-week high for Aclaris Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aclaris Therapeutics Inc 52 week high is $5.17 as of September 08, 2025.
What is the 52-week low for Aclaris Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aclaris Therapeutics Inc 52 week low is $1.05 as of September 08, 2025.
What is Aclaris Therapeutics Inc stock price today?
Aclaris Therapeutics Inc stock price today is $2.10.
What was Aclaris Therapeutics Inc stock price yesterday?
Aclaris Therapeutics Inc stock price yesterday was $2.07.
What is the PE ratio of Aclaris Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Aclaris Therapeutics Inc’s P/E ratio is -1.53.
What is the Price-to-Book ratio of Aclaris Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Aclaris Therapeutics Inc P/B ratio is 1.7268.
What is the 50-day moving average of Aclaris Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aclaris Therapeutics Inc 50-day moving average is $1.66.
How many employess does Aclaris Therapeutics Inc has?